Article

Recovery is hopeful for optic neuritis patients

A 15-year follow-up study was conducted with patients who had acute optic neuritis. Researchers concluded that ophthalmologists can advise acute optic neuritis patients that the long-term results of treating their condition is favorable.

San Francisco-A 15-year follow-up study was conducted with 454 patients who had acute optic neuritis and participated in the Optic Neuritis Treatment Trial (ONTT), a 1988 to 1991 randomized clinical trial. The Optic Neuritis Study Group who conducted the follow-up study concluded that ophthalmologists can advise acute optic neuritis patients that the long-term results of treating their condition is favorable, even if they currently have or develop multiple sclerosis (MS).

From the original ONTT cohort, 294 patients completed the follow-up exam in 2006. Seventy-two percent of the patients had 20/20 vision or better in the affected eye and 66% had 20/20 or better vision in both eyes. Mild decreases in vision were attributed to lens changes in nine patients, which according to researchers, would be expected in an age group with an average age of 48.

Between individuals who were treated with high-dose intravenous corticosteroids and patients who were not, long-term vision quality was similar, although the initial recovery period was shorter for treated patients.

MS patients were more likely to report somewhat reduced quality of life, even though their vision was found to be normal 60% of the time.. According to researchers, patients had difficulty parking a car, using a computer, and experienced double vision and difficulty focusing on moving objects.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.